NeoGenomics

Company profile

About NeoGenomics

NeoGenomics is a leader in oncology diagnostics, specializing in precision medicine and genomics for cancer care. The company provides an extensive portfolio of over 500 tests covering all major testing modalities, including single-gene molecular testing, immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), DNA- and RNA-based next-generation sequencing (NGS), and comprehensive genomic profiling (CGP). NeoGenomics serves three primary markets: healthcare providers seeking precision oncology testing to support personalized patient care, biopharma partners developing cancer therapies and conducting clinical trials, and patients navigating their cancer treatment journey. The company's testing solutions span solid tumors and hematologic cancers, offering advanced tissue-based, liquid biopsy, and hematology tests. Key product lines include the PanTracer portfolio for comprehensive genomic profiling, RaDaR ST for minimal residual disease detection with sensitivity down to 1 part per million, and disease-specific panels for lung, breast, colorectal, gastric, gynecologic, and hematologic cancers. NeoGenomics maintains a database of over 2 million patient profiles from more than 40,000 unique providers across 4,000 healthcare organizations, providing oncology data solutions that deliver insights across the cancer care continuum. The company's mission centers on advancing personalized cancer care through scientific excellence, integrated solutions, and meaningful impact throughout the patient treatment journey.

Company description · NeoGenomics official website